InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.245

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$153 Convening Period Extended to 27 January 2027 28 Oct 2026 4:55PM $0.245 $0.245 fallen by 0%
$153 Deferral of AGM and Financial Reporting Obligations 23 Oct 2026 8:49AM $0.245 $0.245 fallen by 0%
$153 Extension of Convening Period 23 Oct 2026 8:48AM $0.245 $0.245 fallen by 0%
$153 Notification of cessation of securities - PAR 23 Oct 2026 8:48AM $0.245 $0.245 fallen by 0%
$153 Further Agreed Convertible Note Redemption 23 Oct 2026 8:48AM $0.245 $0.245 fallen by 0%
$153 Notification of cessation of securities - PAR 23 Oct 2026 8:48AM $0.245 $0.245 fallen by 0%
$153 PPS Shows Significant Pain Benefit in Rest of World Analysis 15 Oct 2026 2:57PM $0.245 $0.245 fallen by 0%
$153 Expiry of PAROB Listed Options 12 Oct 2026 3:12PM $0.245 $0.245 fallen by 0%
$153 Notification of cessation of securities - PAR 8 Oct 2026 5:31PM $0.245 $0.245 fallen by 0%
$153 Update on Data Review and Convertible note redemption 8 Oct 2026 5:24PM $0.245 $0.245 fallen by 0%
$153 Continuation of Suspension from Quotation 30 Sep 2026 9:56AM $0.245 $0.245 fallen by 0%
$153 Appointment of Voluntary Administrators 30 Sep 2026 9:51AM $0.245 $0.245 fallen by 0%
$153 Board Initiates Voluntary Administration 30 Sep 2026 9:47AM $0.245 $0.245 fallen by 0%
$153 Continuation of Voluntary Suspension 28 Sep 2026 9:45AM $0.245 $0.245 fallen by 0%
$153 Notification of cessation of securities - PAR 24 Sep 2026 3:40PM $0.245 $0.245 fallen by 0%
$153 Agreement to Return US$2M to Obsidian 24 Sep 2026 3:25PM $0.245 $0.245 fallen by 0%
$153 Phase 3 Interim Result Below Continuation Threshold 23 Sep 2026 2:37PM $0.245 $0.245 fallen by 0%
$153 Suspension from Quotation 23 Sep 2026 9:01AM $0.245 $0.245 fallen by 0%
$153 Trading Halt 21 Sep 2026 8:47AM $0.245 $0.245 fallen by 0%
$153 Application for quotation of securities - PAR 18 Sep 2026 11:13AM $0.245 $0.245 fallen by 0%
$153 Dr Daniel Furtner appointed Chief Medical Officer 15 Sep 2026 9:46AM $0.240 $0.245 risen by 2.08%
$153 Application for quotation of securities - PAR 14 Sep 2026 4:08PM $0.238 $0.245 risen by 3.16%
$153 Notice under Section 708A 11 Sep 2026 12:57PM $0.245 $0.245 fallen by 0%
$153 Notification regarding unquoted securities - PAR 11 Sep 2026 12:32PM $0.245 $0.245 fallen by 0%
$153 Drawdown of Tranche 4 under the Convertible Note Facility 11 Sep 2026 12:19PM $0.260 $0.245 fallen by 5.77%

1 - 25 of 751 results

Page 1 of 31

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.